Interestingly, treating HER2+ PTEN- breast cancer cells continually with the HER2-targeting antibody Trastuzumab was observed to induce EMT, convert the disease to a triple-negative breast cancer, increase cancer stem cell frequency, and enhance metastatic potential [17]. Here, ERBB2 is linked to breast carcinoma.